MARATTO

article · The Egyptian Journal of Hospital Medicine

Visual Outcomes of Glaucomatous Patients after Phacoemulsification

2024Open accessSohag University

Abstract

Background: Angle closure glaucoma represent one of main causes of irreversible visual loss due to optic atrophy caused by too high intra ocular pressure. Objectives:The current study aimed to assess visual outcomes of glaucomatous patients after phacoemulsification. Patients and methods: Twenty individuals with primary angle closure glaucoma (PACG) and cataract grade II or higher were included in this investigation. Every participant had a thorough eye examination and had their visual acuity measured either before or after surgery. Uncorrected visual acuity (UCVA) and best corrected visual acuity (BCVA), presented as a logarithm of the minimum angle of resolution (logMAR), were the primary research outcome measurements. Results: Regarding mean baseline and follow up values of UCVA of the phaco group, the mean baseline was (1.03 ± 0.187), at 1 week was (0.66 ± 0.187), at 1 month was (0.63 ± 0.192), at 3 months and 6 months was (0.60 ± 0.145). Regarding mean baseline and follow up values of BCVA of the phaco group, the mean baseline was (0.86 ± 0.252), at 1 week was (0.50 ± 0.182), at 1 month was (0.46 ± 0.154), at 3 months and 6 months was (0.45 ± 0.147). Conclusions: Phacoemulsification in cases with primary angle closure glaucoma is connected to improved UCVA and BCVA up to 6 months follow-up.

Research topics

  • Ocular Diseases and Behçet’s Syndrome
  • Cerebral Venous Sinus Thrombosis
  • Glaucoma and retinal disorders

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/ejhm.2024.344770

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.